Overview

Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal

Status:
Completed

Trial end date:
2019-04-23

Target enrollment:

Participant gender:

Summary

This study is an open-label, randomized, fed, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tamsulosin HCl Tablet" and Astellas Phama Korea Inc. "Harnal-D" in healthy volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Tamsulosin